Formulation Development
SPECIAL FEATURE - PFS & Parenteral Delivery: Innovation Is Focused on Patient-Centric, Smart & Sustainable Solutions
Contributor Cindy H. Dubin speaks with several innovating companies to discuss trends in PFS as well as advancements in autoinjectors and innovations in parenteral delivery.
TRANSDERMAL DELIVERY - SkinJect’s Doxorubicin-Loaded Dissolvable Microneedle Array (D-MNA): A Revolutionary Approach to Transdermal Drug Delivery
Raza Bokhari, MD, Edward Brennan, MD, FACS, and Madison Weisz, MS, explore the D-MNA treatment, highlighting its drug delivery mechanisms, advantages over traditional treatments, and clinical potential.
Aenova Launches Aenovation(TM) Program to Accelerate Pharmaceutical Development
Aenova, a leading contract development and manufacturing organization (CDMO) in the global pharmaceutical supply chain, recently announced the launch of its innovative Aenovation(TM) program. This…
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
FORMULATION FORUM - Self-Emulsifying Drug Delivery Systems for Improving Oral Bioavailability of Drugs
Jim Huang, PhD, and Shaukat Ali, PhD, say as more NCEs continue to be discovered with less options to find the appropriate excipients and solubilizers for Class II and IV drugs, the pharma industry has begun to evaluate liquid SEDDS for expediting drugs to market.
EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
NASAL DRUG DELIVERY - Overcoming the Challenges of Formulation Development
Eric Kaneps explores the nasal drug delivery landscape, including the benefits of nasal administration compared with other routes and the unique formulation challenges associated with this delivery method.
EXECUTIVE INTERVIEW - Salipro Biotech & Bio-Rad Laboratories: A Powerful Solution for Antibody Discovery Against Challenging Transmembrane Targets
Dr. Jens Frauenfeld, CEO, Salipro Biotech, and Dr. Francisco Ylera, R&D Team Lead at Bio-Rad Laboratories, explain how their collaboration is leveraging the Salipro® platform alongside Bio-Rad’s Pioneer™ Antibody Discovery Platform to target transmembrane proteins.
THERAPEUTIC FOCUS - Targeting Chronic Inflammation in Obesity
Johnny Peppers, PhD, and Christopher Mojcik, MD, PhD, explore the connection of obesity and inflammation, the current treatment landscape, and directions for future treatment.
DRUG DEVELOPMENT - The Next Frontier in Immunotherapy for Ovarian Cancer
Khursheed Anwer, PhD, MBA, and Douglas V. Faller, MD, PhD, highlight a new delivery system (TheraPlas®) being used to develop a more localized IL-12 immunotherapy for ovarian cancer and review its promising Phase 2 results.
EXECUTIVE INTERVIEW - Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System
Nathan Givoni, Co-Founder and CEO of Gelteq, discusses challenges with traditional drug delivery and the company’s innovative ingestible gel platform designed for drug and nutrient delivery.
Sitryx Nominates Novel Oral MTHFD2 Inhibitor for Clinical Development in Psoriatic Arthritis
Sitryx Therapeutics recently announced the nomination of SIT-047, a novel, oral MTHFD2 inhibitor, as the latest development candidate from its proprietary pipeline to progress to…
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy Candidate
Opus Genetics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment…
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis & Other Inflammatory Bowel Diseases
Palisade Bio, Inc. recently announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients…
Vetter Prioritizes Continuity & Action in its Sustainability Efforts
Vetter published its fourth annual sustainability report. The report shows that the family-owned business is actively pursuing ambitious sustainability goals in climate protection, social responsibility,…
Aptar CSP Technologies Expands Service Offerings With Launch of cGMP Early Stage Clinical Manufacturing Site for Tablet & Capsule-Based Drug Products
Aptar CSP Technologies, part of AptarGroup, Inc. and a global leader in active material science solutions, announced the expansion of its service offerings with the…
Roquette Announces New Organization Following Acquisition of IFF Pharma Solutions
Roquette recently announced a new organization following the successful acquisition of IFF Pharma Solutions announced on May 1. The new organization is designed to enhance…
Can-Fite Has Raised $175 Million for the Development of Namodenoson & Piclidenoson
Can-Fite BioPharma Ltd. recently announced it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates,…
Immutep’s Efti in Combination With KEYTRUDA Drives Strong Overall Survival in Head & Neck Cancer With CPS <1
Immutep Limited recently announced an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb…
Moleculin Bolsters Annamycin Intellectual Property Portfolio With Granting of Two New U.S. Patents
Moleculin Biotech, Inc. recently announced the US Patent and Trademark Office (USPTO) has granted two additional US patents with claims covering Annamycin. US patent number…
